{
    "clinical_study": {
        "@rank": "72456", 
        "arm_group": {
            "arm_group_label": "EPO906", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study will examine whether the investigational drug EPO906, given by intravenous\n      infusion (IV directly into the vein), is effective in shrinking tumors and preventing the\n      growth of cells that cause kidney cancer."
        }, 
        "brief_title": "EPO906 Therapy in Patients With Advanced Kidney Cancer", 
        "condition": "Kidney Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Kidney Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        The following patients may be eligible for this study:\n\n          -  Histologically or cytologically documented evidence of epithelial renal cell\n             carcinoma with at least one measurable lesion (if previous radiation treatment, the\n             target lesion must have demonstrated progression since the radiation)\n\n          -  Patients must have had a prior nephrectomy\n\n          -  Must have a life expectancy of greater than three (3) months\n\n          -  Patients who have had 0-1 prior cytokine treatment regimen (i.e. IL-2, IFN-?) or\n             relapsed less than one year after such treatment may be eligible.\n\n        Exclusion Criteria:\n\n        The following patients are not eligible for this study:\n\n          -  Patients who have received more than one (1) prior cytokine regimen (i.e. IL-2, IFN?)\n             or relapsed more than one year after receiving such treatment are not eligible\n\n          -  Patients who have had any prior chemotherapy (including a combination therapy)\n\n          -  Patients with symptomatic CNS metastases or leptomeningeal involvement\n\n          -  Patients with any peripheral neuropathy or unresolved diarrhea greater than Grade 1\n\n          -  Patients with severe cardiac insufficiency\n\n          -  Patients taking Coumadin or other warfarin-containing agents with the exception of\n             low dose Coumadin (1 mg or less) for the maintenance of in-dwelling lines or ports\n\n          -  History of another malignancy within 3 years prior to study entry except curatively\n             treated non-melanoma skin cancer, prostate cancer, or cervical cancer in situ\n\n          -  Patients with active or suspected acute or chronic uncontrolled infection including\n             abcesses or fistulae\n\n          -  HIV+ patients\n\n          -  Pregnant or lactating females."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "53", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 2, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_alias": "NCT00041002", 
            "nct_id": "NCT00035243", 
            "org_study_id": "CEPO906A2207"
        }, 
        "intervention": {
            "arm_group_label": "EPO906", 
            "description": "EPO906 administered intravenously at 2.5 mg/m2 as a 5 minute bolus infusion repeated every week for three weeks followed by one week off The final tables and data is not in yet, so I cannot give you info on safety issues.", 
            "intervention_name": "epothilone b", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Epothilone B", 
                "Epothilones"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "kidney cancer", 
            "renal cancer", 
            "cancer", 
            "tumor", 
            "tumour", 
            "neoplasm", 
            "carcinoma", 
            "clear cell", 
            "sarcomatoid", 
            "papillary", 
            "medullary", 
            "collecting duct", 
            "chromophobe", 
            "intravenous", 
            "epothilone"
        ], 
        "lastchanged_date": "April 16, 2012", 
        "link": {
            "description": "Visit NovartisClinicalTrials.com: Pre-qualify for a trial, and view a list of trials and participating study centers.", 
            "url": "http://www.novartisclinicaltrials.com/etrials/searchTrial.do?trialID=608"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095"
                    }, 
                    "name": "UCLA Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21201"
                    }, 
                    "name": "University of Maryland"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }, 
                    "name": "Wayne State University Karmanos Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bronx", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10466"
                    }, 
                    "name": "Our Lady Of Mercy Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44195"
                    }, 
                    "name": "Cleveland Clinic Foundation"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98109"
                    }, 
                    "name": "University of Washington"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France"
                    }, 
                    "name": "Centre L. Berard"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villejuif", 
                        "country": "France"
                    }, 
                    "name": "Institut Gustave Roussy"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "France"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Renal Cancer", 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2003", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Tumor response as assessed by radiologic techniques and/or physical examination based on Response Evaluation Criteria in Solid Tumors (RECIST)", 
            "safety_issue": "No", 
            "time_frame": "every 8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00035243"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Objective response rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "every 8 weeks"
            }, 
            {
                "measure": "Time to disease progression (TTP)", 
                "safety_issue": "No", 
                "time_frame": "every 8 weeks"
            }, 
            {
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "every 8 weeks"
            }, 
            {
                "measure": "Safety and tolerability  of EPO906", 
                "safety_issue": "Yes", 
                "time_frame": "at each visit"
            }, 
            {
                "description": "For biomarker development", 
                "measure": "Tumor-specific mutations  and gene expression changes in tumor cells with blood cells and plasma", 
                "safety_issue": "No", 
                "time_frame": "prior to the first treatment with EPO906, on the day of any clinically indicated tumor biopsy/resection and on the day of each tumor assessment"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2002", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2012"
    }, 
    "geocoordinates": {
        "Centre L. Berard": "45.764 4.836", 
        "Cleveland Clinic Foundation": "41.499 -81.695", 
        "Institut Gustave Roussy": "48.793 2.359", 
        "Our Lady Of Mercy Medical Center": "40.85 -73.867", 
        "UCLA Medical Center": "34.052 -118.244", 
        "University of Maryland": "39.29 -76.612", 
        "University of Washington": "47.606 -122.332", 
        "Wayne State University Karmanos Cancer Center": "42.331 -83.046"
    }
}